Table 1 Clinicopathologic features of patients with MDS vs. AML with t(6;9)(p22;q34).
Overall (N = 107) | MDS (N = 33) | AML (N = 74) | p value | |
|---|---|---|---|---|
Age, median (range, years) | 43 [10–82] | 51 [22–74] | 38 [10–82] | 0.10 |
Gender (male, %) | 55/107 (51%) | 18/33 (55%) | 37/74 (50%) | 0.68 |
Peripheral blood, median (range) | ||||
WBC (×109/L) | 9.5 (0.4–222.2) | 3.2 (0.9–61.2) | 15.3 (0.4–222.2) | 0.0017 |
Hgb (g/dL) | 8.4 (4.4–13.9) | 8.6 (4.6–13.0) | 8.3 (4.4–13.9) | 0.22 |
Platelets (×109/L) | 59 (12–373) | 85 (18–242) | 52 (12–373) | 0.022 |
Blasts (%) | 6% (0–97%) | 0% (0–12%) | 12% (0–97%) | <0.0001 |
Basophils (%) | 0% (0–3%) | 0% (0–2%) | 0% (0–3%) | 0.61 |
Bone marrow | ||||
Blasts, median (range, %) | 45% (2–90%) | 11% (2–19%) | 56% (20–90%) | <0.0001 |
Basophils, median (range, %) | 0% (0–4%) | 0% (0–2%) | 0% (0–4%) | 0.1 |
Dyserythropoiesis, N (%) | 75/99 (75%) | 26/30 (87%) | 49/69 (70%) | 0.083 |
Dysgranulopoiesis, N (%) | 63/99 (64%) | 21/30 (70%) | 42/69 (61%) | 0.5 |
Dysmegakaryopoiesis, N (%) | 55/99 (56%) | 25/30 (83%) | 30/69 (43%) | 0.0003 |
Multilineage dysplasia, N (%) | 69/99 (70%) | 27/30 (90%) | 42/69 (61%) | 0.004 |
Karyotype | ||||
Complex, N (%) | 9/92 (10%) | 2/26 (8%) | 7/66 (11%) | >0.99 |
Sole t(6;9), N (%) | 67/92 (73%) | 22/26 (85%) | 45/66 (68%) | 0.13 |
FLT3-ITD, N (%) | 61/79 (77%) | 10/19 (53%) | 51/60 (85%) | 0.01 |
Transplant, N (%) | 69/107 (64%) | 20/33 (61%) | 49/74 (66%) | 0.66 |
F/U time, median (range, mos) | 24 (1–160) | 32 [6–94] | 20 (1–160) | 0.06 |
Patient outcome, N (death, %) | 60/107 (56%) | 17/33 (52%) | 43/74 (58%) | 0.54 |
